Questions?
REQUEST A MEDICAL SCIENCE LIAISON (MSL)
Questions?
REQUEST A MEDICAL SCIENCE LIAISON (MSL)
#1 MOST-PRESCRIBED
oral prostacyclin pathway therapy in PAH in the US3
UPTRAVI® is the only prostacyclin pathway therapy indicated to delay disease progression AND reduce risk of PAH-related hospitalization2
GRIPHON: the FIRST and ONLY completed PAH outcomes trial that included patients treated with triple-combination therapy2,4
FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; WHO=World Health Organization.
Clicking continue below will take you to the selected site, the content for which Janssen is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
The following form is intended for use with patients
who are eligible for VA benefits only.
After the starting dose of 200 mcg twice daily, all patients completed titration to their maintenance dose within the first 12 weeks, up to a maximum dose of 1600 mcg twice daily.
After the starting dose of 200 mcg twice daily, all patients completed titration to their maintenance dose within the first 12 weeks, up to a maximum dose of 1600 mcg twice daily.
